2024-03-29T15:18:12Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/93262023-10-05T05:44:17Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2146
00925njm 22002777a 4500
dc
Mason, Christian A
author
Kossatz, Susanne
author
Carter, Lukas M
author
Pirovano, Giacomo
author
Brand, Christian
author
Guru, Navjot
author
Perez-Medina, Carlos
author
Lewis, Jason S
author
Mulder, Willem J M
author
Reiner, Thomas
author
2020-03
The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL) nanotracer as a means of monitoring response to immunotherapy. Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of 89Zr-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. Results: A significant reduction in 89Zr-HDL accumulation was observed in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated ex vivo and correlated with decreased TAM density. Conclusion: These results support the potential use of 89Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.
J Nucl Med. 2020; 61(3):433-436
0161-5505
http://hdl.handle.net/20.500.12105/9326
31420495
10.2967/jnumed.119.230466
1535-5667
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
CSF1R inhibitor
HDL
PET/CT imaging
Immunotherapy
Tumor-associated macrophages
An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor